Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NHS wins legal fight with pharma over off-label Avastin

NHS wins legal fight with pharma over off-label Avastin

and Novartis’Lucentis  to treat wet AMD, claiming that it broke EU and UK laws governing medicines licensing. ... The cost implications are clear, as the court judgement showed: it says Avastin’s list price is around £28 per injection; Eylea around

Bayer to challenge Avastin legal ruling

Bayer to challenge Avastin legal ruling age-related macular degeneration (wet AMD) in place of two licensed but much more expensive treatments, Bayer’s Eylea and Novartis’Lucentis. ... carried out to establish its equivalence in safety and efficacy with Lucentis in particular.

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug. Next gen eye treatment offers less frequent dosing. ... of Lucentis and Eylea for AMD, even though Avastin isn’t approved for the indication.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III Allergan’ s abicipar matches AMD blockbuster Lucentis in phase III. Bayer's Eylea remains the drug to beat, however. ... Allergan and partner Molecular Partners say a pair of two studies of abicipar show that the drug is non-inferior to monthly dosing

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics